BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70 with cervical cancer that has spread or come back and cannot be cured with surgery or radiation.
- Your tumor must have a high level of a protein called PD-L1 (CPS 1 or higher) based on a recent biopsy.
- You have not already received systemic (whole-body) treatment for this advanced stage of cervical cancer.
- You have at least one tumor that can be measured on a scan, and you are in good enough health to have a life expectancy of at least 12 weeks.
- You are not pregnant, use effective birth control if needed, and are willing to follow all study procedures.
- You have not had certain prior treatments like immune checkpoint inhibitors, and you do not have serious infections, uncontrolled autoimmune disease, or major heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This Phase 2 trial tests cadonilimab (an immunotherapy) combined with nab-paclitaxel (chemo) to treat cervical cancer that has come back or spread and did not respond to prior immune checkpoint medicines. It may help shrink tumors and improve disease control after prior immunotherapy failure.
This trial tests whether chemotherapy plus an immune treatment called PD-1, along with radiation, can help people with cervical cancer that cannot be removed with surgery. It’s aimed at locally advanced, unresectable cervical squamous cell cancer.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.